论文部分内容阅读
目的探讨替罗非班治疗急性ST段抬高型心肌梗死(STEMI)的临床疗效。方法将我院2009年8月至2010年4月收治的60例STEMI患者分为治疗组和对照组,对照组采用常规治疗,治疗组在对照组的基础上采用替罗非班治疗,比较两组患者的临床疗效。结果治疗组的总有效率为83.3%显著高于对照组的66.7%(P<0.05);且治疗组的hs-CRP的改善显著优于对照组(P<0.05)。结论替罗非班是治疗STEMI较为有效的抗栓药物,其能显著降低患者的炎性反应,缓解症状。
Objective To investigate the clinical efficacy of tirofiban in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Methods Sixty STEMI patients treated in our hospital from August 2009 to April 2010 were divided into treatment group and control group. The control group was treated with conventional therapy. The treatment group was treated with tirofiban on the basis of the control group. Group of patients with clinical efficacy. Results The total effective rate of the treatment group was 83.3%, which was significantly higher than that of the control group (66.7%, P <0.05). The improvement of hs-CRP in the treatment group was significantly better than that of the control group (P <0.05). Conclusion Tirofiban is an effective anti-thrombotic agent for the treatment of STEMI, which can significantly reduce the patient’s inflammatory response and relieve symptoms.